Association of Objective Subtle Cognitive Difficulties with Amyloid-β and Tau Deposition Compared to Subjective Cognitive Decline

Overview

Journal Eur J Nucl Med Mol Imaging

Date 2025 Jan 21

PMID 39836215

Authors

Xiaoxie Mao

Anqi Li

Ying Wang

Yan Wang

Shuhua Ren

Kun He

Yihui Guan

Qi Huang

Qihao Guo

Zijing Li

Tengfei Guo

Fang Xie

Affiliations

Soon will be listed here.

Abstract

Purpose: This study evaluated the differences in amyloid-β (Aβ), tau deposition, and longitudinal tau deposition between subjective cognitive decline (SCD) and objective subtle cognitive difficulties (Obj-SCD).

Methods: Participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort (n = 234) and the Huashan cohort (n = 267) included individuals with Obj-SCD, SCD, subjective memory concern (SMC), and healthy controls (HC). General linear models (GLM) were used to compare baseline and longitudinal differences in Aβ and tau among the groups, and to examine the associations between these biomarkers.

Results: Obj-SCD participants had significantly higher Aβ and tau levels compared to HC, with increased annual accumulation of Aβ and tau, especially in Braak stages III-IV. In contrast, SCD/SMC participants did not show significant differences from HC in annual Aβ and tau changes. Baseline Aβ PET correlated with annual tau PET changes in Obj-SCD (Braak III-VI) and SCD/SMC (all Braak stages), and baseline Aβ levels strongly predicted early memory decline in both Obj-SCD and SCD/SMC groups.

Conclusion: This study indicates that Obj-SCD is more strongly associated with Aβ and tau biomarkers, with Aβ contributing to the progression of tau pathology and memory decline. Further research should include more longitudinal data to more robustly validate these findings and clarify the temporal relationship between Aβ and tau in preclinical Alzheimer's disease.

References

Sperling R, Aisen P, Beckett L, Bennett D, Craft S, Fagan A . Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7(3):280-92. PMC: 3220946. DOI: 10.1016/j.jalz.2011.03.003. View

Dubois B, Hampel H, Feldman H, Scheltens P, Aisen P, Andrieu S . Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016; 12(3):292-323. PMC: 6417794. DOI: 10.1016/j.jalz.2016.02.002. View

Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K . Alzheimer's disease drug development pipeline: 2020. Alzheimers Dement (N Y). 2020; 6(1):e12050. PMC: 7364858. DOI: 10.1002/trc2.12050. View

Jessen F, Amariglio R, van Boxtel M, Breteler M, Ceccaldi M, Chetelat G . A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement. 2014; 10(6):844-52. PMC: 4317324. DOI: 10.1016/j.jalz.2014.01.001. View

Lee J, Ju Y, Park E, Lee S . Effect of poor sleep quality on subjective cognitive decline (SCD) or SCD-related functional difficulties: Results from 220,000 nationwide general populations without dementia. J Affect Disord. 2019; 260:32-37. DOI: 10.1016/j.jad.2019.08.082. View

Oliver M, Morrison C, Kamal F, Graham J, Dadar M . Subjective cognitive decline is a better marker for future cognitive decline in females than in males. Alzheimers Res Ther. 2022; 14(1):197. PMC: 9798694. DOI: 10.1186/s13195-022-01138-w. View

Thomas K, Edmonds E, Eppig J, Salmon D, Bondi M . Using Neuropsychological Process Scores to Identify Subtle Cognitive Decline and Predict Progression to Mild Cognitive Impairment. J Alzheimers Dis. 2018; 64(1):195-204. PMC: 7263028. DOI: 10.3233/JAD-180229. View

Edmonds E, Delano-Wood L, Galasko D, Salmon D, Bondi M . Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's Disease. J Alzheimers Dis. 2015; 47(1):231-42. PMC: 4634634. DOI: 10.3233/JAD-150128. View

Thomas K, Bangen K, Weigand A, Edmonds E, Wong C, Cooper S . Objective subtle cognitive difficulties predict future amyloid accumulation and neurodegeneration. Neurology. 2020; 94(4):e397-e406. PMC: 7079691. DOI: 10.1212/WNL.0000000000008838. View

10.

Ren S, Li J, Huang L, Huang Q, Chen K, Hu J . Brain Functional Alterations and Association with Cognition in People with Preclinical Subjective Cognitive Decline and Objective Subtle Cognitive Difficulties. Neuroscience. 2023; 513:137-144. DOI: 10.1016/j.neuroscience.2023.01.004. View

11.

Huang Y, Li Y, Xie F, Guo Q . Associations of plasma phosphorylated tau181 and neurofilament light chain with brain amyloid burden and cognition in objectively defined subtle cognitive decline patients. CNS Neurosci Ther. 2022; 28(12):2195-2205. PMC: 9627371. DOI: 10.1111/cns.13962. View

12.

Jones J, Uribe C, Bunch J, Thomas K . Beyond PD-MCI: objectively defined subtle cognitive decline predicts future cognitive and functional changes. J Neurol. 2020; 268(1):337-345. PMC: 7855683. DOI: 10.1007/s00415-020-10163-4. View

13.

Thomas K, Eppig J, Edmonds E, Jacobs D, Libon D, Au R . Word-list intrusion errors predict progression to mild cognitive impairment. Neuropsychology. 2018; 32(2):235-245. PMC: 5851458. DOI: 10.1037/neu0000413. View

14.

Spires-Jones T, Hyman B . The intersection of amyloid beta and tau at synapses in Alzheimer's disease. Neuron. 2014; 82(4):756-71. PMC: 4135182. DOI: 10.1016/j.neuron.2014.05.004. View

15.

Bateman R, Xiong C, Benzinger T, Fagan A, Goate A, Fox N . Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012; 367(9):795-804. PMC: 3474597. DOI: 10.1056/NEJMoa1202753. View

16.

Buckley R, Hanseeuw B, Schultz A, Vannini P, Aghjayan S, Properzi M . Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global β-Amyloid Burden. JAMA Neurol. 2017; 74(12):1455-1463. PMC: 5774633. DOI: 10.1001/jamaneurol.2017.2216. View

17.

Thomas K, Weigand A, Edwards L, Edmonds E, Bangen K, Ortiz G . Tau levels are higher in objective subtle cognitive decline but not subjective memory complaint. Alzheimers Res Ther. 2022; 14(1):114. PMC: 9394026. DOI: 10.1186/s13195-022-01060-1. View

18.

Boccalini C, Ribaldi F, Hristovska I, Arnone A, Peretti D, Mu L . The impact of tau deposition and hypometabolism on cognitive impairment and longitudinal cognitive decline. Alzheimers Dement. 2023; 20(1):221-233. PMC: 10916991. DOI: 10.1002/alz.13355. View

19.

Beckett L, Donohue M, Wang C, Aisen P, Harvey D, Saito N . The Alzheimer's Disease Neuroimaging Initiative phase 2: Increasing the length, breadth, and depth of our understanding. Alzheimers Dement. 2015; 11(7):823-31. PMC: 4510463. DOI: 10.1016/j.jalz.2015.05.004. View

20.

Thomas K, Bangen K, Edmonds E, Weigand A, Walker K, Bondi M . Objective subtle cognitive decline and plasma phosphorylated tau181: Early markers of Alzheimer's disease-related declines. Alzheimers Dement (Amst). 2021; 13(1):e12238. PMC: 8515224. DOI: 10.1002/dad2.12238. View